Accession Number:

ADA393144

Title:

Daily 1-alpha-OH-D2 in Hormone Refractory Prostate Cancer: Assessment of Clinical and Biochemical Effects

Descriptive Note:

Final rept. 1 Aug 1998-31 Jan 2001

Corporate Author:

WISCONSIN UNIV-MADISON

Personal Author(s):

Report Date:

2001-02-01

Pagination or Media Count:

14.0

Abstract:

The goals of this proposal were to examine the clinical effectiveness of vitamin D analog therapy l-alpha hydroxyvitamin D2 in patients with advanced androgen-independent prostate cancer. We performed a phase II study of l-alpha hydroxyvitamin D2 administered daily at doses from 12.5 to 5.0 ugday and examined various laboratory correlative studies for any correlation with outcome. Daily administration of l-alpha hydroxyvitamin D2 was well tolerated with occasional grade 1 and rare grade 2 hypercalcemia. No objective tumor responses were observed but 6 out of 20 evaluable patients had stable disease for greater than or less than 6 months. Treatment with 1-alpha hydroxyvitamin D2 was associated with decreased serum PTH levels and increased urine calcium levels. Plasma TGF-beta-1 levels and T cell receptor zeta chain analysis in peripheral T cells did not correlate with clinical outcome as related to vitamin D-based therapy. These findings support further study of the potential clinical effectiveness of vitamin D-based therapies in advanced prostate cancer.

Subject Categories:

  • Biochemistry
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE